Pharma

Weighing the Cost of Semaglutide

New US study evaluates the cost-effectiveness of semaglutide in treating non-diabetic patients with obesity and cardiovascular disease.

Pfizer Pulls Out of Hemophilia B Gene Therapy, Signaling a Shift in Strategy

Pfizer has announced it will no longer develop or sell Beqvez, its hemophilia B gene therapy, in any global markets.

Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Initiatives

Moderna reported sales of $3.1 billion, the comapny states this is a 53% decline from 2023. Read about the steps being taken to combat this decline in performance.

Sanofi's Dupixent Receives FDA Priority Review for Bullous Pemphigoid Treatment

Dupixent has received FDA priority review for the treatment of bullous pemphigoid, a rare autoimmune skin disorder. If approved, Dupixent would become the first targeted therapy for BP, offering a safer and more effective treatment option.

Novo Nordisk Unveils Promising Weight Loss Results from Amycretin Clinical Trial

Innovative GLP-1 and amylin receptor agonist shows up to 22% weight reduction in early-stage study.

Novartis' Intrathecal Onasemnogene Abeparvovec Phase III Study Meets Primary Endpoint

Novartis' Phase III study of intrathecal onasemnogene abeparvovec for spinal muscular atrophy (SMA) successfully met its primary endpoint, showing significant motor function improvements.